These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28947118)

  • 1. New symptomatic therapies for Huntington disease.
    Deb A; Frank S; Testa CM
    Handb Clin Neurol; 2017; 144():199-207. PubMed ID: 28947118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
    Squitieri F; de Yebenes JG
    Drug Des Devel Ther; 2015; 9():5827-33. PubMed ID: 26604684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS; McGarry A; Ma Q; Kieburtz K
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting mutant huntingtin for the development of disease-modifying therapy.
    Appl T; Kaltenbach L; Lo DC; Terstappen GC
    Drug Discov Today; 2012 Nov; 17(21-22):1217-23. PubMed ID: 22772050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pridopidine for the treatment of Huntington's disease.
    Shannon KM
    Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical management of motor manifestations of Huntington disease.
    McCusker EA; Loy CT
    Handb Clin Neurol; 2017; 144():141-150. PubMed ID: 28947112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Huntington's Disease-Update on Treatments.
    Wyant KJ; Ridder AJ; Dayalu P
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):33. PubMed ID: 28324302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The psychopharmacology of Huntington disease.
    Petersén Å; Weydt P
    Handb Clin Neurol; 2019; 165():179-189. PubMed ID: 31727211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the therapeutic development for Huntington disease.
    Mestre TA
    Parkinsonism Relat Disord; 2019 Feb; 59():125-130. PubMed ID: 30616867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
    Kusko R; Dreymann J; Ross J; Cha Y; Escalante-Chong R; Garcia-Miralles M; Tan LJ; Burczynski ME; Zeskind B; Laifenfeld D; Pouladi M; Geva M; Grossman I; Hayden MR
    Mol Neurodegener; 2018 May; 13(1):25. PubMed ID: 29783994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treadmill exercise delays the onset of non-motor behaviors and striatal pathology in the CAG
    Stefanko DP; Shah VD; Yamasaki WK; Petzinger GM; Jakowec MW
    Neurobiol Dis; 2017 Sep; 105():15-32. PubMed ID: 28502806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review.
    Claassen DO; Iyer RG; Shah-Manek B; DiBonaventura M; Abler V; Sung VW
    J Huntingtons Dis; 2018; 7(4):345-353. PubMed ID: 30282372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options for Huntington's disease.
    Grimbergen YA; Roos RA
    Curr Opin Investig Drugs; 2003 Jan; 4(1):51-4. PubMed ID: 12625029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.
    Tippett LJ; Waldvogel HJ; Snell RG; Vonsattel JP; Young AB; Faull RLM
    Adv Neurobiol; 2017; 15():129-161. PubMed ID: 28674980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
    Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
    J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foundation-directed therapeutic development in Huntington's disease.
    Dominguez C; Munoz-Sanjuan I
    J Med Chem; 2014 Jul; 57(13):5479-88. PubMed ID: 24432836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
    Ryskamp D; Wu J; Geva M; Kusko R; Grossman I; Hayden M; Bezprozvanny I
    Neurobiol Dis; 2017 Jan; 97(Pt A):46-59. PubMed ID: 27818324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions in therapeutics for Huntington disease.
    Potkin KT; Potkin SG
    Future Neurol; 2018 May; 13(2):101-121. PubMed ID: 30800004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexistence of Gait Disturbances and Chorea in Experimental Huntington's Disease.
    Casaca-Carreira J; Temel Y; van Zelst M; Jahanshahi A
    Behav Neurol; 2015; 2015():970204. PubMed ID: 26063966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.